rawfin.tv
Seastar Medical Targets NEUTRALIZE-AKI Enrollment Completion by Early 2027
MarketsstocksAI Generated

Seastar Medical Targets NEUTRALIZE-AKI Enrollment Completion by Early 2027

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Seastar Medical aims to complete enrollment for its NEUTRALIZE-AKI trial around year-end or Q1 2027, marking a significant clinical milestone. Concurrently, the company's QUELIMMUNE product has achieved adoption in 20 hospitals.

Seastar MedicalBiotechClinical TrialsMedical DevicesHospital Adoption

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks